We investigated perforations, bleeding, and splenic injuries after screening or diagnostic colonoscopies to identify patient-, procedure-, endoscopist-, and facility-associated risk factors.
C olorectal cancer is a major cause of morbidity and mortality. 1 The French colorectal cancer screening program invites all adults 50-74 years of age to undergo a fecal occult blood test, followed by colonoscopy in the case of a positive fecal occult blood test. The fecal occult blood test has recently been changed from a stool guaiac test to a more sensitive fecal immunochemical test, which will probably further increase the number of colonoscopies performed in France.
The safety of colonoscopy is a critical issue. Many studies have reported severe adverse event (SAE) rates associated with colonoscopy. Three recent systematic reviews and meta-analyses summarized the results of these studies, [2] [3] [4] provided perforation and bleeding rates after colonoscopies, and showed that SAEs were more frequent after diagnostic colonoscopy compared with screening colonoscopy and that polypectomies were associated with higher SAE rates. Medical administrative databases are an alternative to meta-analyses to assess rare events, as they are based on very large populations. In a previous study, French National Health Insurance estimated the risks of gastrointestinal perforation and bleeding after colonoscopies for any indication, and reported factors associated with these complications in France.
The present study was based on French National Health Insurance databases, over the period 2010-2015. It was designed to estimate the SAE rates (perforations, major bleeding, splenic injuries) associated with screening or diagnostic colonoscopies, and identify risk factors associated with these complications. Based on our findings, we propose several measures to reduce SAE rates after screening or diagnostic colonoscopy.
Methods

Data Sources
A cohort study was conducted using French medical administrative databases. Individual data were extracted from both the SNIIRAM (National Health Insurance Claims Information System) and PMSI (National Hospital Discharge Database). These databases provide detailed information on health insurance claims for inpatient (PMSI) and outpatient (SNIIRAM) care for 99% of the population living in France (about 67,000,000 people). 6 This study was approved by the French data protection agency (regulatory decision DE-2015-165) .
The SNIIRAM database contains data about all outpatient services reimbursed by National Health Insurance, but does not provide any information about the medical indications. Patients with chronic diseases (longterm disease [LTD] ) are 100% reimbursed for their healthcare expenditure, and the diagnosis is recorded in the SNIIRAM (International Classification of DiseasesTenth Revision [ICD-10] codes). The PMSI database contains the procedures performed during all hospital stays (notably, colonoscopies), and the principal (DP), related (DR), and associated diagnoses (ICD-10 codes). Procedures are coded according to the French medical classification for clinical procedures. Detailed presentation of the SNIIRAM/PMSI databases is available in the online Supplementary appendix.
Study Population
The study population included national health insurance general scheme beneficiaries aged 30 years and over, who underwent colonoscopy between January 1, 2010, and December 31, 2015 (procedure codes in Supplementary Table 1 ). The study population was restricted to general scheme beneficiaries because reliable information on the date of death is always available in this insurance scheme. Overall, 76% of persons living in France are covered by the general scheme. 6 To estimate the complication rates of screening or diagnostic colonoscopies, patients with a history of chronic inflammatory bowel disease (ICD-10 codes K50-K51), colorectal cancer (C18-C21) or complicated diverticular disease of intestine requiring inpatient care (K57) were excluded. The presence of these conditions was determined during the 24 months preceding colonoscopy in the PMSI database (hospitalization diagnoses) and in the SNIIRAM (LTD diagnoses). Other conditions resulting in colorectal surgery during the 24 months preceding colonoscopy were also excluded (procedure codes in Supplementary Table 2 ). In addition, only the first colonoscopy of the study period was included in the study, and the absence of another colonoscopy performed during the previous 24 months was checked (notably in [2008] [2009] ). Emergency colonoscopies (at night or on Sundays), or on or after day 3 of hospitalization were not considered to be screening or diagnostic colonoscopies and were therefore excluded from the cohort.
Colonoscopy
Three types of colonoscopy were distinguished according to the information available in the French classification of clinical procedures: colonoscopies without resection or destruction of polyps, colonoscopies with resection or destruction of 1-3 polyps <1 cm in diameter, and colonoscopies with resection of 1 polyp larger than 1 cm in diameter or 4 or more polyps. The databases do not contain information about polyp location. Bowel preparation was identified in the SNIIRAM by reimbursement of a polyethylene glycol, phosphate, or magnesium preparation during the 6 months preceding the colonoscopy.
Severe Adverse Events
SAEs were identified by discharge diagnoses (DP, DR, and associated diagnosis) of the hospitalization for colonoscopy or readmission during the 5 days following colonoscopy. SAEs were also identified by medical or What You Need to Know Background Screening colonoscopies are associated with a low risk of severe local adverse events: colonic perforations, gastrointestinal bleeding, and splenic injuries. These complications can be associated with patient, procedure, endoscopist, and facility characteristics.
Findings
Perforations and bleeding related to screening and diagnostic colonoscopies were more frequent in older patients, patients with cancer and cardiovascular disease and with less experienced endoscopists. Splenic injury rate was 0.20 per 10,000 procedures.
Implications for patient care
Patients at risk of severe adverse events should be identified and colonoscopies in these patients should be performed or supervised by experienced endoscopists.
surgical procedures on the colon or rectum, performed in hospital within 5 days after colonoscopy when the main diagnosis of hospitalization (DP or DR) was not colorectal neoplasm, inflammatory bowel disease, or diverticular disease of intestine.
Three types of SAEs of colonoscopy were investigated: perforations, major bleeding, and splenic injuries. Each of these complications was defined according to stringent and broad definitions. Stringent definitions included specific ICD-10 codes of colonoscopy SAEs, and broad definitions included less specific ICD-10 codes and procedures that can identify SAEs not captured by stringent definitions. ICD-10 codes used for stringent and broad definitions of SAEs are presented in Supplementary Table 3 , and procedure codes added to the broad definitions are presented in Supplementary  Tables 4, 5 , and 6. Death date, identified in the SNIIRAM, was used to estimate 5-and 30-day mortality for each SAE.
Covariates
The 14 comorbidities included in the Charlson index 7 were evaluated: myocardial infarct, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disease, ulcer disease, moderate or severe renal disease, hemiplegia, human immunodeficiency virus/acquired immunodeficiency syndrome, liver disease (mild, and moderate or severe liver disease), diabetes (with and without end-organ damage), cancer (nonmetastatic cancer and metastatic solid tumor). They were identified in the SNIIRAM-PMSI databases during the 3 years preceding colonoscopy, from 4 information sources: in-hospital diagnoses, LTD diagnoses, specific medical procedures performed during a hospital stay, and specific medications, as described elsewhere. 8 Antiplatelet and anticoagulant drug reimbursements were also identified in the SNIIRAM during the 6 months preceding colonoscopy.
Private practice endoscopists, the only practitioners identified in the SNIIRAM (but performing threequarters of all colonoscopies), were classified according to the number of years since their medical doctor (MD) graduation, and the number of procedures performed during the 12 months preceding the colonoscopy. Institutions were classified according to their administrative status (university/local public hospital, or private for-profit or not-for-profit clinics), and the mean annual number of colonoscopies performed in the institution during the study period.
Statistical Analysis
Crude SAE rates (perforation, bleeding, or splenic injury) per 10,000 colonoscopies were calculated by dividing the total numbers of SAEs by the total number of colonoscopies in the cohort, with a minimum and a maximum rate estimated respectively by the stringent and broad definition for each SAE. Crude 5-day and 30-day mortality rates per 1000 SAEs were calculated for each SAEs by dividing the total numbers of deaths occurring within 5 or 30 days by the total number of SAEs in the cohort. Crude odds ratios for SAEs (perforation or bleeding) were estimated by logistic regression models for patient, colonoscopy, endoscopist, and facility characteristics. Random-intercept multilevel logistic regression models, adjusting for patient, colonoscopy, and endoscopist characteristics, were estimated separately for perforations and bleeding (stringent definitions). These analyses were restricted to colonoscopies for which the endoscopist (and his or her MD graduation year) could be identified, i.e. those performed by private practice endoscopists. Comorbidities and antiplatelet or anticoagulant use were kept in the multivariate models when they remained significantly associated with the outcome in multivariate analysis (with P values <.05). In sensitivity analyses, patients for whom bowel preparation could not be identified in the SNIIRAM database were excluded, due to a proportion of missing values.
Statistical analyses were performed with SAS Enterprise Guide 7.1 (SAS Institute, Cary, NC).
Results
More than 4,600,000 patients 30 years of age and over undergoing a first colonoscopy between 2010 and 2015 were identified; 262,883 patients were excluded due to comorbidities diagnosed before the colonoscopy and 223,816 patients in whom colonoscopy performed was performed on day 3 of hospitalization or later were also excluded. The final cohort therefore comprised 4,088,799 patients ( Figure 1 ).
Baseline characteristics of study participants are presented in Table 1 . A slight majority of the colonoscopies were performed in women (55%), almost 3 of 4 patients were 50 years of age or older, and 70% of patients presented no comorbidity. One-third of colonoscopies comprised polypectomy, and almost all (97.5%) colonoscopies were performed with sedation. The majority of colonoscopies were performed in private for-profit clinics (73%). The majority of colonoscopies performed by private practice endoscopists were performed by male endoscopists (85%), with 15 or more years of experience (87%).
The perforation rate ranged from 3.5 (stringent definition) to 7.3 per 10,000 procedures (broad definition). The bleeding rate ranged from 6.5 to 23.1 per 10,000 procedures, and the splenic injury rate ranged from 0.20 to 0.34 per 10,000 procedures. The 30-day mortality rate after SAEs was 29.2 per 1000 perforations (stringent definition), 13.2 per 1000 bleeds, and 36.1 per 1000 splenic injuries (Table 2) . Forty-eight (35%) patients with splenic injury did not present any of the comorbidities included in the Charlson index (data not shown), and more than 60% (n ¼ 88) of splenic injuries occurred in patients 60 years of age or older.
Univariate analyses are presented in Supplementary  Table 7 . Associations between hospital characteristics and risks of perforation or bleeding were no longer significant in single-level multivariate analysis, whereas endoscopist characteristics remained significant. Facility factors were therefore excluded from the final analyses and multilevel models were constructed accounting for patients nested within endoscopists. Multilevel analyses were restricted to colonoscopies for which the endoscopist could be identified (3,057,260 patients, nested within 2233 endoscopists). Baseline characteristics and crude odds ratios for perforation and bleeding in these 3 million patients were similar to those of the complete cohort, but with lower comorbidity rates and a higher proportion (96%) of colonoscopies performed in private for-profit clinics. These data are presented in Supplementary Tables 8 group vs the 30-39 years of age group). Comorbidities significantly associated with perforation in multilevel multivariate analysis (Table 3) were cancer (particularly, metastatic solid tumor: aOR, 6.96; 95% CI, 5.08-9.53), connective tissue disease, moderate or severe renal disease, peripheral vascular disease, and chronic pulmonary disease (aOR, 1.20-1.82). Polypectomies larger than 1 cm (or excision of 4 or more polyps) were associated with a fourfold higher risk of perforation. The association between the endoscopist's number of years since MD graduation and perforation tended to be U-shaped, with a significantly 2-fold higher risk for endoscopists with less than 5 years of experience compared with endoscopists with 15-24 years of experience (graphical representation of the univariate association between perforation rate and endoscopist's number of years since MD graduation is available in Supplementary Figure 1) . Finally, the risk of perforation increased with the decreasing number of colonoscopies performed each year by the endoscopist. Sensitivity analysis restricted to patients for whom bowel preparation was retrieved was consistent with the main analysis (Supplementary Table 11 ).
In multilevel multivariate analysis (Table 4) , only the older age group (80 yearsof age and older) was associated with an increase in bleeding risk (aOR, 1.95 compared with patients 30-39 years of age; 95% CI, 1.44-2.63). Comorbidities remaining significantly associated with bleeding were cancer (particularly, metastatic solid tumor: aOR, 4.75; 95% CI, 3.65-6.18), liver disease, moderate or severe renal disease, peripheral vascular disease, congestive heart failure, and cerebrovascular disease (aOR from 1.33 to 1.99). Polypectomies were associated with a significant increase in bleeding risk, particularly those larger than 1 cm (aOR, 13.3; 95% CI, 11.7-15.1). The younger the endoscopist was (since his or her MD graduation), the higher the bleeding risk was, with for instance a 30% increase in bleeding risk for endoscopists graduated 5-14 years before colonoscopy, compared with those graduated 15-24 years before. As in univariate analysis, there was no independent association between the number of colonoscopies performed by the endoscopist during the previous year and the risk of bleeding. Sensitivity analysis restricted on patients for whom bowel preparation was identified was in keeping with the main analysis (Supplementary Table 12 ).
Discussion
Colonoscopies performed for screening or primary diagnosis in France were associated with 3.5-7.3 perforations, 6.5-23.1 bleeds, and 0.20-0.34 splenic injuries per 10,000 procedures. These SAEs are life-threatening: 0.4-0.8 deaths occurred within 5 days per 1000 bleeds, and 6.3-11.3 per 1000 perforations. Polypectomy (notably when larger than 1 cm, as highlighted by other authors) 9 was associated with an increased risk of perforation and bleeding. Increasing age was associated with an increasing risk for both of these complications, especially perforations. Patients with cancer or cardiovascular disease had a higher risk of perforation or bleeding. In multivariate analysis, endoscopist characteristics (experience and annual number of procedures) were associated with the risks of SAEs. No facility characteristics were associated with these risks.
The perforation and bleeding rates (according to stringent definitions) estimated in this study are similar to those of a recent review performed for the U.S. Preventive Services Task Force (4 perforations and 8 major bleeds per 10,000 colonoscopies), 2 based on 26 and 22 studies, respectively. These concordant results suggest that our algorithm adequately identified patients undergoing screening or diagnostic colonoscopies, and the associated SAEs. The polypectomy rate in our population was therefore low (33%). In a recent study based on medical administrative data, Wang et al 10 found a 59% biopsy or intervention rate in screening or surveillance colonoscopies. Our algorithm excluded surveillance colonoscopies, which probably explains why our findings differed to such an extent.
Studies on the SAEs associated with colonoscopy often lack sufficient statistical power to investigate rare SAEs such as splenic injuries, and the U.S. Preventive Services Task Force underlined the lack of data about this SAE. 2 Our estimated rate of splenic injury was 0.20-0.34 per 10,000 procedures (83-139 of 4,088,799 colonoscopies). A previous retrospective study found splenic injury in 7 of 296,248 colonoscopies performed between 1980 and 2008 in a single institution (ie, 0.2 per 10,000 procedures). 11 Another study reported a rate of 0.72 per 10,000 procedures (12 of 165,527 colonoscopies). 12 However, the authors did not restrict their population to the first colonoscopy and their patients were older; these 2 factors could have contributed to the higher rate of splenic injury observed in their study. 13 Finally, a recent study reported 0.41 splenic injuries per 10,000 anaesthesia-assisted colonoscopies (36 of 826,817) and 0.46 per 10,000 unassisted colonoscopies (102 of 2,196,228).
14 These rates are higher than those reported in the present study (even our maximum rate) and this discordance could be explained by possible underdeclaration in our database (as suggested by our 5-day mortality rate of 0 for splenic injury). This study shows that SAEs are associated with endoscopist rather than facility characteristics. Adjusting for both endoscopist and hospital characteristics in single-level models resulted in statistically nonsignificant associations for hospital characteristics, leading to the exclusion of these factors from the final multilevel analyses. A large proportion of the association between hospital factors and SAEs may therefore be confounded by endoscopists characteristics, in addition to patients characteristics. Chukmaitov et al 15 recently showed that patients treated in freestanding ambulatory surgery centers had higher risks of perforations and bleeding than those treated in hospital outpatient departments in the United States. Unfortunately, although they adjusted their analyses for patient comorbidities, the authors were unable to adjust their analyses for endoscopist characteristics. 15 Several studies have also found that the endoscopist's number of procedures 5, 16 and number of years since MD graduation were correlated with a lower number of SAEs. 5 Colonoscopy learning curves have shown that more than 200 procedures are needed to reach technical competence for colonoscopy, 17 and European guidelines recommend that endoscopists involved in colorectal cancer screening perform at least 300 colonoscopies each year. 18 Interestingly, our results suggest that the relationship between the endoscopist's age and the perforation rate tends to be U-shaped with a higher risk for younger and older physicians, after adjustment for the number of procedures performed each year.
Our study takes full advantage of the SNIIRAM-PMSI databases. 6 This comprehensive French medical administrative database, comprising full linkage, minimizes the number of cases lost to follow-up. We built a cohort of more than 4 million individuals, and were able to robustly describe rare events such as splenic injuries and SAE-related mortality, and assess separate comorbidities instead of an overall comorbidity score, such as the Charlson index. Nevertheless, to study endoscopistassociated characteristics, we had to restrict our analyses to colonoscopies for which the endoscopist could be identified (ie, private practice endoscopists), leading to the exclusion of most colonoscopies performed in public hospitals. The sample included more than 3 million individuals with similar characteristics to those of the original cohort, except that they presented fewer comorbidities. A slight majority of patients in the cohort were women (55%). This may be partly explained by the slightly better participation of women in the national colorectal cancer screening program (33% vs 29% in men in 2012-2013).
19 Also, 2233 endoscopists were identified between 2010 and 2015, which is consistent with the 2030 private practice gastroenterologists identified in the 2013 French National Medical Council census. 20 Minimum rates of SAEs (according to stringent definitions) were modeled to promote measurement validity, and then specificity by minimizing nondifferential measurement errors. 21 Multilevel logistic regression was used to model risks associated with SAEs. Multilevel analysis is relevant to assess the impact of macro-level endoscopist characteristics on individual-level risk of perforation or bleeding. 22 Single-level analysis underestimates the variance of contextual variable estimators (eg, endoscopist characteristics), and may therefore lead to spurious conclusions.
The main limitation of this study is that we were unable to confirm whether colonoscopies were performed for screening, diagnosis, or treatment purposes, as this information is not available in the SNIIRAM-PMSI. 6 No direct comparison between these data and chart review is available in France (for either screening and diagnostic colonoscopies, or for their complications). Nevertheless, SAE rates were similar to those reported in recent meta-analyses, [2] [3] [4] tending to support the validity of our algorithm. The inclusion of patients in our cohort in whom colonoscopies were performed on day 1 or 2 of hospitalization ensured that SAEs identified by means of hospitalization diagnoses occurred after colonoscopy. The quality of identification of SAEs depends on the coding accuracy of physicians or medical coding professionals, which can be considered to be fair, 6 although limited by ICD-10 precision. Finally, we were unable to assess the impact of the type of sedation on SAEs. Wernli et al 23 emphasized that the use of propofol for colonoscopy sedation was associated with an increased risk of complications. Sedation is widely used in France for colonoscopies (97.5% in our screening or diagnostic colonoscopy population) and, according to a recent French survey, deep sedation is used in more than 90% of colonoscopies. 24 Confirming or invalidating Wernli et al's 23 results would have been of great public health interest. Unfortunately, the information about sedation associated with colonoscopy available in the French classification of clinical procedures only indicates whether or not the patient was sedated, but does not provide any information about the type of sedation received. The type of sedation cannot be determined, as all colonoscopies in France ("inpatient" as well as "outpatient" colonoscopies) are performed in hospital, and the drugs used during hospitalization (especially those used for sedation) are not available in the PMSI database.
The findings of this study are important for clinical practice. We suggest that patients at high risk for SAEs should be identified and colonoscopies in these patients should be performed or supervised by experienced endoscopists (ie, those performing more than 300 procedures per year and with more than 15 years of certification). The results suggest that less invasive methods for colorectal cancer screening, such as virtual colonoscopy or computed tomography colonography, should be considered in patients at high risk of SAEs.
In conclusion, SAEs of colonoscopies for screening and primary diagnosis purposes are associated with patient's age and comorbidities, as well as with the endoscopist's experience. Patients at risk of SAEs should be identified and colonoscopies in these patients should be performed or supervised by experienced endoscopists.
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Presentation of the SNIIRAM/PMSI Databases
The study was conducted using French medical administrative databases. Individual data were extracted from both the SNIIRAM (Système National d'Information Inter-Régime de l'Assurance Maladie [National Health Insurance Claims Information System]) and PMSI (Programme de Médicalisation des Systèmes d'Information [National Hospital Discharge Database]). These databases were linked by means of a unique anonymous number allocated to each individual, providing detailed information on health insurance claims for inpatient (PMSI) and outpatient (SNIIRAM) care for 99% of the population living in France (about 67,000,000 people). Further description of these databases and their use is available in English in the papers by Bezin et al 1 and Moulis et al, 2 and more extensively in the paper by Tuppin et al. 3 The SNIIRAM database contains data about all outpatient services reimbursed by National Health Insurance, including drugs, physician visits, and laboratory investigations, but does not provide any information about the medical indications. Patients with chronic diseases (long-term disease [LTD]), such as cancer or Crohn's disease, are 100% reimbursed for their health expenditure, and the diagnosis is recorded in the SNIIRAM (coded according to International Classification of Diseases-Tenth Revision [ICD-10] codes). 4 The accuracy of medication use estimated on the basis of SNIIRAM data has been previously investigated: drugs with the best agreements between SNIIRAM data and patient interviews were antidiabetic and cardiovascular drugs (kappa values >0.80) 5 ; the sensitivity of drug exposure was 85.3% with a specificity of 91% for antithrombotics. 6 The PMSI database contains the procedures performed during all hospital stays (notably, colonoscopies), and the principal (DP), related (DR), and associated (DAS) diagnoses (coded according to ICD-10). DP and DR correspond to the diseases justifying admission to hospital, and DAS are comorbidities or adverse events treated during the hospitalization. In order to be recorded as a hospitalization diagnosis in the PMSI (DP, DR, or DAS), the diagnosis therefore had to have an impact on medical care. Procedures are coded according to the French medical classification for clinical procedures (CCAM [Classification commune des actes médicaux]). 7 The PMSI database does not contain any information about the inpatient or outpatient status, which cannot be deduced from other data. Drugs used during hospitalization (notably, those used for sedation) are not available in the PMSI, except for certain expensive drugs (such as some types of cancer chemotherapy). Dates available in the PMSI are admission date, discharge date, and procedure (eg, colonoscopy) date. For the purposes of this study, admission date was used as an approximation for the serious adverse event date.
Almost all persons living in France are covered by one of the various national health insurance schemes. Each national health insurance scheme reimburses almost all medical care (including colonoscopies) at the same rate for both public and private care. Persons with limited income or LTD are 100% reimbursed. The general scheme is the largest health insurance scheme in France (covering 76% of the population living in France). This scheme includes employed workers, retired, unemployed, and disadvantaged people. Follow-up of beneficiaries is stable, as people rarely leave this scheme. Other schemes (mainly farmers and self-employed) are more specific. The present study was restricted to the general scheme, as reliable information (notably on death date) for the entire study period is only available for this scheme.
SNIIRAM and PMSI data are commonly used for noninterventional studies in various conditions. To date, more than 400 published studies have used these databases 3 (and associated references). [8] [9] [10] [11] [12] [13] [14] [15] These comprehensive national databases are powerful tools to assess the prevalence of rare events. As the primary purpose of these databases is financial, any false statements constitute serious frauds, liable to legal proceedings, which also tends to ensure the accuracy of the data recorded. Furthermore, quality controls and audits are performed before transmission to National Health Insurance (CNAM, Caisse Nationale de l'Assurance Maladie), mainly for processing of aberrant or missing data. Hemostasis of colon injury with laser by complete colonoscopy HJSD001
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Hemostasis secondary to a procedure on the rectum FELF003 Simultaneous intravenous administration of two of the following blood products: fresh frozen plasma, platelets, antihemophilic factor, fibrinogen, antithrombin III for coagulopathy, per 24 h FELF001
Packed red blood cell transfusion with a volume greater than one half of the blood volume during an operation under general or locoregional anesthesia FELF004
Packed red blood cell transfusion with a volume greater than one half of the blood volume in adults or 40 mL/kg in newborns in <24 h FELF011
Packed red blood cell transfusion with a volume less than one half of the blood volume FELF006
Transfusion of nonerythrocyte labile blood product NOTE. CCAM (Classification Commune des Actes Médicaux) is the French medical classification of medical procedures. 
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